• Expanding Total Addressable Market (TAM) from $455M to $3.5B+ through portfolio expansion and efficient execution
• Positioned for leadership in the $3.5B+ U.S. acute wound care market
• Sustained revenue growth with 47% CAGR through 2025

AVITA Medical's Q1 2025 earnings presentation outlines the company's strategic growth initiatives and financial performance. The key highlights include the expansion of the company's Total Addressable Market (TAM) from $455M in 2019 to a $3.5B+ opportunity in the acute wound care segment, driven by a multi-product portfolio strategy and efficient execution. AVITA is positioned to be a leader in the $3.5B+ U.S. acute wound care market, leveraging its innovative product offerings such as RECELL, Cohealyx, and PermeaDerm. The presentation also showcases AVITA's sustained revenue growth, with a 47% compound annual growth rate (CAGR) projected through 2025. The company's financial performance and forward-looking guidance demonstrate its ability to capitalize on the growing acute wound care market and deliver value to its shareholders.

AVITA Medical expects to achieve commercial revenue of $100-$106 million in the fiscal year 2025, representing a 47% CAGR through December 30, 2025.